ABBV · AbbVie Inc.
$251.522026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$147
-41.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($112 · $272) Analysts Range ($223 · $298) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $54.3B | — | 24.7% | 20.3% | $10.7B | $711MM | $11.4B | 5.6% | — | 11.8% | $90.6B | $2.74 | — |
| 2024.Q4 | $54.3B | 0.0% | 24.7% | 0.0% | $15.5B | −$16.5B | −$970MM | 6.5% | — | 17.0% | $91.6B | $2.74 | — |
| 2025.Q1 | $56.3B | 3.7% | 17.1% | 0.0% | $11.2B | −$11.0B | $139MM | 6.0% | — | 11.0% | $110.6B | $2.41 | — |
| 2025.Q4 | $56.3B | 0.0% | 17.1% | 35.8% | $6.2B | $5.9B | $12.0B | 5.6% | — | 5.7% | $104.1B | $2.41 | — |
| 2026.Q1 | $62.8B | 11.5% | 29.1% | 39.1% | $11.1B | $6.1B | $17.2B | 5.6% | — | 9.8% | $122.6B | $2.05 | 24.4 |
| italics below = DCF projection · 10yr Rev CAGR: 5.5% |
| 2027.Q1 | $68.7B | +9.3% | 30.6% | 37.2% | $13.2B | −$3.8B | $9.3B | 5.8% | $8.8B | 10.6% | $126.4B | $6.71 | 37.5 |
| 2028.Q1 | $74.1B | +7.9% | 30.3% | 35.3% | $14.5B | −$4.6B | $9.9B | 6.1% | $8.9B | 11.3% | $131.0B | $7.47 | 33.7 |
| 2029.Q1 | $79.2B | +6.9% | 30.0% | 33.3% | $15.8B | −$6.0B | $9.8B | 6.4% | $8.2B | 11.8% | $137.0B | $8.21 | 30.6 |
| 2030.Q1 | $82.9B | +4.7% | 29.7% | 31.4% | $16.9B | $0MM | $16.9B | 6.7% | $13.2B | 12.3% | $137.0B | $8.85 | 28.4 |
| 2031.Q1 | $86.7B | +4.6% | 29.1% | 29.5% | $17.8B | $0MM | $17.8B | 6.9% | $13.0B | 13.0% | $137.0B | $9.51 | 26.4 |
|
| Term. Yr+ | $111.3B | 4.1% | 29.1% | 20.0% | $25.9B | −$8.1B | $17.8B | 8.6% | $199.7B | 13.1% | — | — | — |
Active scenario IV: $147 (-41.5% vs market)